Authors/Disclosures
|
Guido Davidzon, MD
|
No disclosure on file |
|
|
No disclosure on file |
|
Karl D. Kieburtz, MD
(University of Rochester Medical Center)
|
Dr. Kieburtz has received personal compensation for serving as an employee of Clintrex Research Corporation. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Kieburtz has stock in Clintrex Research Corp. Dr. Kieburtz has stock in Hoover Brown. An immediate family member of Dr. Kieburtz has stock in Hoover Brown. Dr. Kieburtz has stock in Safe Therapeutics. The institution of Dr. Kieburtz has received research support from NIH. The institution of Dr. Kieburtz has received research support from Michae J Fox Foundation. |
|
Oliver Neuhaus, MD
(Dept Neurology, SRH Kliniken Landkreis Sigmaringen)
|
No disclosure on file |
|
Michelangelo Mancuso, MD
(Neurological Clinic)
|
No disclosure on file |
|
C. W. Olanow, MD
|
Dr. Olanow has received personal compensation for serving as an employee of Clintrex Research Corporation. Dr. Olanow has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Clintrex Research Corporation. Dr. Olanow has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Chevron/Syngenta. Dr. Olanow has stock in Clintrex Research Corporation. |
|
|
No disclosure on file |
|
J. E. Ahlskog, MD, PhD
(Mayo Clinic)
|
Dr. Ahlskog has received publishing royalties from a publication relating to health care. |
|
Yael Cohen
|
Yael Cohen has nothing to disclose. |
|
|
No disclosure on file |
|
Kevin Klos, MD
(The Movement Disorder Clinic of Oklahoma)
|
The institution of Dr. Klos has received research support from Sunovion. The institution of Dr. Klos has received research support from Roche. The institution of Dr. Klos has received research support from Impax. The institution of Dr. Klos has received research support from Prilenia. The institution of Dr. Klos has received research support from Enterin. |
|
Tamar Rachmilewitz
|
No disclosure on file |
|
|
No disclosure on file |
|
Paul E. Greene, MD
|
No disclosure on file |
|
|
No disclosure on file |
|
Michio Hirano, MD, FAAN
(Columbia University Medical Center)
|
Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Biopharma SRL. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precision Biosciences. Dr. Hirano has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Biopharma SRL. Dr. Hirano has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apollo Communication. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Envision Communications. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for 好色先生. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Cure SMA. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Muscular Dystrophy Association. The institution of Dr. Hirano has received research support from UCB. The institution of Dr. Hirano has received research support from Cyclerion. Dr. Hirano has received research support from Reneo Pharmaceuticals. The institution of Dr. Hirano has received research support from Astellas. Dr. Hirano has received intellectual property interests from a discovery or technology relating to health care. Dr. Hirano has received intellectual property interests from a discovery or technology relating to health care. Dr. Hirano has received personal compensation in the range of $0-$499 for serving as a Study Section Reviewer with NIH. Dr. Hirano has a non-compensated relationship as a Research Advisory Board member with Muscular Dystrophy Association that is relevant to AAN interests or activities. Dr. Hirano has a non-compensated relationship as a Scientific and Medical Advisory Board member with United Mitochondrial Disease Foundation that is relevant to AAN interests or activities. Dr. Hirano has a non-compensated relationship as a Scientific Advisory Board member with Barth Syndrome Foundation that is relevant to AAN interests or activities. |
|
|
No disclosure on file |
|
Salvatore DiMauro, MD
(Columbia University Medical Center)
|
No disclosure on file |